주식/증권
➡️ 중립
Biogen’s Alzheimer’s Drug Fell Short of Targets. Why the Stock Is Rising Anyway.
요약
Biogen’s diranersen showed ‘robust reductions’ in key biomarkers during a Phase 2 trial, the biotech said.